PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
02-Mar-2022 International Society for Cell & Gene Therapy establishes working group to tackle regulatory and ethical issues with Expanded Access International Society for Cell & Gene Therapy
02-Mar-2022 Glucophage® is the First Oral Diabetes Treatment Approved in Europe for use during Pregnancy Merck
02-Mar-2022 Santhera Signs Gene Therapy Agreement with SEAL Therapeutics Santhera Pharmaceuticals
02-Mar-2022 Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients Vifor Pharma Group
02-Mar-2022 Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis Sanofi
02-Mar-2022 Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria Sanofi
02-Mar-2022 FDA Accepts for Review Pfizer’s Supplemental Application for ABRILADA™ (adalimumab-afzb) Interchangeability Pfizer Inc.
02-Mar-2022 Evotec presents strategic roadmap towards precision medicine and confirms goals of Action Plan 2025 at Capital Markets Day Evotec SE
01-Mar-2022 AEVIS VICTORIA SA (AEVS:SW): Hotel division acquires hotel L'Oscar in central London for GBP 60 million. AEVIS VICTORIA SA
01-Mar-2022 Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients Takeda
01-Mar-2022 Medicines and Healthcare Products Regulatory Authority (MHRA) issues Great Britain Marketing Authorisation for Aspaveli®▼ (pegcetacoplan) in adults with paroxysmal nocturnal haemoglobinuria Sobi
01-Mar-2022 CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer(R) CureVac
01-Mar-2022 AstraZeneca and Neurimmune close exclusive global collaboration and licence agreement to develop and commercialise NI006 AstraZeneca and Neurimmune
01-Mar-2022 BioMed X Institute and Boehringer Ingelheim Start New Research Project in Brain Sensor Development B3C newswire
01-Mar-2022 Nordic Nanovector ASA: Results for the Fourth Quarter and Full Year 2021 Nordic Nanovector ASA
01-Mar-2022 New treatment option for patients with SHPT ‒ Rayaldee® now available in Switzerland Vifor Pharma Switzerland Ltd.
01-Mar-2022 Long term study confirms efficacy of ISA Pharmaceuticals’ T-cell activating immunotherapy in combination with checkpoint inhibitor ISA Pharmaceuticals B.V.
01-Mar-2022 Evotec expands molecular patient database with unique nephrotic syndrome cohort from the University of Bristol Evotec SE
28-Feb-2022 MediClin AG: Disclosure of the preliminary figures for the 2021 financial year - result above expectations thanks to better capacity utilization in the 4th quarter of 2021 MediClin AG
28-Feb-2022 Defence Therapeutics Inc.: DEFENCE RELEASES PEER-REVIEWED PUBLICATION OF ITS PRECLINICAL DATA ON ACCUVAC-D001L IN CELL REPORTS MEDICINE JOURNAL Defence Therapeutics Inc.